Peregrine Asset Advisers, Inc. Gilead Sciences, Inc. Transaction History

Peregrine Asset Advisers, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$57.92 - $72.58 $249,056 - $312,094	-4,300 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$67.69 - $73.03 $291,067 - $314,029	4,300 New	4,300 $300,000
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $260,424 - $302,400	-3,600 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $225,468 - $288,792	3,600 New	3,600 $269,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Peregrine Asset Advisers, Inc., based on Form 13F filings with the SEC.

Stay updated on Peregrine Asset Advisers, Inc. with notifications on news.